BACKGROUND & AIMS:Large-volume paracentesis (LVP) is the treatment of choice for patients with cirrhosis and refractory ascites. However, LVP can lead to postparacentesis circulatory dysfunction (PCD), which is associated with faster ascites recurrence and renal failure. PCD results from vasodilatation, which reduces effective blood volume, and is prevented by intravenous administration of albumin. Vasoconstrictors could be used instead of albumin and, with longer use, prevent PCD and delay ascites recurrence. METHODS: We performed a multicenter, randomized, double-blind, placebo-controlled trial to compare albumin with the vasoconstrictor combination of octreotide and midodrine in patients with refractory ascites who underwent LVP. Patients in the albumin group received a single intravenous dose of albumin at the time of LVP plus placebos for midodrine and octreotide (n = 13). Patients in the vasoconstrictor group received saline solution (as a placebo for albumin), 10 mg of oral midodrine (3 times/day), and a monthly 20-mg intramuscular injection of long-acting octreotide (n = 12). Patients were followed up until recurrence of ascites. RESULTS: The median times to recurrence of ascites were 10 days in the albumin group and 8 days in the vasoconstrictor group (P = .318). There were no significant differences in PCD between the albumin group (18%) and the vasoconstrictor group (25%, P = .574). When ascites recurred, serum levels of creatinine were higher in the vasoconstrictor group (1.2 vs 0.9 mg/dL in the albumin group; P = .051). CONCLUSIONS: The combination of midodrine and octreotide after LVP is not superior to albumin in delaying recurrence of ascites or preventing PCD in patients with cirrhosis. Outcomes appear to be worse in patients given octreotide and midodrine. ClinicalTrials.gov number, NCT00108355.
RCT Entities:
BACKGROUND & AIMS: Large-volume paracentesis (LVP) is the treatment of choice for patients with cirrhosis and refractory ascites. However, LVP can lead to postparacentesis circulatory dysfunction (PCD), which is associated with faster ascites recurrence and renal failure. PCD results from vasodilatation, which reduces effective blood volume, and is prevented by intravenous administration of albumin. Vasoconstrictors could be used instead of albumin and, with longer use, prevent PCD and delay ascites recurrence. METHODS: We performed a multicenter, randomized, double-blind, placebo-controlled trial to compare albumin with the vasoconstrictor combination of octreotide and midodrine in patients with refractory ascites who underwent LVP. Patients in the albumin group received a single intravenous dose of albumin at the time of LVP plus placebos for midodrine and octreotide (n = 13). Patients in the vasoconstrictor group received saline solution (as a placebo for albumin), 10 mg of oral midodrine (3 times/day), and a monthly 20-mg intramuscular injection of long-acting octreotide (n = 12). Patients were followed up until recurrence of ascites. RESULTS: The median times to recurrence of ascites were 10 days in the albumin group and 8 days in the vasoconstrictor group (P = .318). There were no significant differences in PCD between the albumin group (18%) and the vasoconstrictor group (25%, P = .574). When ascites recurred, serum levels of creatinine were higher in the vasoconstrictor group (1.2 vs 0.9 mg/dL in the albumin group; P = .051). CONCLUSIONS: The combination of midodrine and octreotide after LVP is not superior to albumin in delaying recurrence of ascites or preventing PCD in patients with cirrhosis. Outcomes appear to be worse in patients given octreotide and midodrine. ClinicalTrials.gov number, NCT00108355.
Authors: P Angeli; R Volpin; G Gerunda; R Craighero; P Roner; R Merenda; P Amodio; A Sticca; L Caregaro; A Maffei-Faccioli; A Gatta Journal: Hepatology Date: 1999-06 Impact factor: 17.425
Authors: Pere Ginès; Juan Uriz; Blas Calahorra; Guadalupe Garcia-Tsao; Patrick S Kamath; Luis Ruiz Del Arbol; Ramón Planas; Jaime Bosch; Vicente Arroyo; Juan Rodés Journal: Gastroenterology Date: 2002-12 Impact factor: 22.682
Authors: R Moreau; T Asselah; B Condat; C de Kerguenec; F Pessione; B Bernard; T Poynard; M Binn; J D Grangé; D Valla; D Lebrec Journal: Gut Date: 2002-01 Impact factor: 23.059
Authors: Javier Sola-Vera; Josep Miñana; Elena Ricart; Montserrat Planella; Begoña González; Xavier Torras; Jose Rodríguez; José Such; Sonia Pascual; Germán Soriano; Miguel Pérez-Mateo; Carlos Guarner Journal: Hepatology Date: 2003-05 Impact factor: 17.425
Authors: A Ginès; G Fernández-Esparrach; A Monescillo; C Vila; E Domènech; R Abecasis; P Angeli; L Ruiz-Del-Arbol; R Planas; R Solà; P Ginès; R Terg; L Inglada; P Vaqué; F Salerno; V Vargas; G Clemente; J C Quer; W Jiménez; V Arroyo; J Rodés Journal: Gastroenterology Date: 1996-10 Impact factor: 22.682
Authors: V Arroyo; P Ginès; A L Gerbes; F J Dudley; P Gentilini; G Laffi; T B Reynolds; H Ring-Larsen; J Schölmerich Journal: Hepatology Date: 1996-01 Impact factor: 17.425
Authors: Kara B Johnson; Jessica L Mueller; Tracey G Simon; Hui Zheng; Lindsay Y King; Robert S Makar; Debra A Gervais; Raymond T Chung Journal: Dig Dis Sci Date: 2015-02-28 Impact factor: 3.199
Authors: Amine Benmassaoud; Suzanne C Freeman; Davide Roccarina; Maria Corina Plaz Torres; Alex J Sutton; Nicola J Cooper; Laura Iogna Prat; Maxine Cowlin; Elisabeth Jane Milne; Neil Hawkins; Brian R Davidson; Chavdar S Pavlov; Douglas Thorburn; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy Journal: Cochrane Database Syst Rev Date: 2020-01-16
Authors: Saqib Walayat; Daniel Martin; Jaymon Patel; Umair Ahmed; Muhammad N Asghar; Aparna U Pai; Sonu Dhillon Journal: J Community Hosp Intern Med Perspect Date: 2017-03-31